Trials / Completed
CompletedNCT01665352
A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes
Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study to Evaluate the Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 186 (actual)
- Sponsor
- vTv Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the safety and effect of TTP054 versus placebo on glucose control in patients with type 2 diabetes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TTP054 | Administered orally once daily for 12 weeks. |
| DRUG | Placebo | Administered orally once daily for 12 weeks. |
Timeline
- Start date
- 2012-08-01
- Primary completion
- 2013-05-01
- Completion
- 2013-05-01
- First posted
- 2012-08-15
- Last updated
- 2017-02-10
Locations
19 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01665352. Inclusion in this directory is not an endorsement.